1 of 5
FEATURED COMPANIES
- AbbVie
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc.
- Johnson & Johnson
- MORE
Biologics Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global biologics market as it emerges from the COVID-19 shut down.
Reasons to Purchase
Where is the largest and fastest growing market for the biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Biologics market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider biologics market, and compares it with other markets.
Markets Covered:
1) By Type: Monoclonal Antibodies (MAbS); Therapeutic Proteins; Vaccines
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs
Subsegments Covered: Anti-Cancer MAbS; Immunological MAbS; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological MABS; Cardiovascular and Cerebrovascular MAbS; Other Monoclonal Antibodies (MAbs); Metabolic Disorders Therapeutic Proteins; Cancer Therapeutic Proteins; Cardiovascular Therapeutic Proteins; Immunological Therapeutic Proteins; Other Therapeutic Proteins; Anti-Infective Vaccines; Autoimmunity Vaccines; Other Vaccines
Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb; GlaxoSmithKline Plc.; AbbVie
Metrics Covered: Number of Enterprises; Number of Employees
Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, biologics indicators comparison.
Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
This report will be delivered within 1-3 business days.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Where is the largest and fastest growing market for the biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Biologics market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider biologics market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
- The biologics market section of the report gives context. It compares the biologics market with other segments of the pharmaceuticals market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, biologics indicators comparison.
Markets Covered:
1) By Type: Monoclonal Antibodies (MAbS); Therapeutic Proteins; Vaccines
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs
Subsegments Covered: Anti-Cancer MAbS; Immunological MAbS; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological MABS; Cardiovascular and Cerebrovascular MAbS; Other Monoclonal Antibodies (MAbs); Metabolic Disorders Therapeutic Proteins; Cancer Therapeutic Proteins; Cardiovascular Therapeutic Proteins; Immunological Therapeutic Proteins; Other Therapeutic Proteins; Anti-Infective Vaccines; Autoimmunity Vaccines; Other Vaccines
Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb; GlaxoSmithKline Plc.; AbbVie
Metrics Covered: Number of Enterprises; Number of Employees
Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, biologics indicators comparison.
Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown
2 of 5
FEATURED COMPANIES
- AbbVie
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc.
- Johnson & Johnson
- MORE
1. Executive Summary
2. Report Structure
3. Biologics Market Characteristics
3.1. Market Definition
3.2. Key Segmentations
4. Biologics Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products
5. Biologics Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers
6. Biologics Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth
7. Biologics Market Trends and Strategies
8. Impact of COVID-19 on Biologics
9. Biologics Market Size and Growth
9.1. Market Size
9.2. Historic Market Growth, Value ($ Billion)
9.2.1. Drivers of the Market
9.2.2. Restraints on the Market
9.3. Forecast Market Growth, Value ($ Billion)
9.3.1. Drivers of the Market
9.3.2. Restraints on the Market
10. Biologics Market Regional Analysis
10.1. Global Biologics Market, 2020, by Region, Value ($ Billion)
10.2. Global Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
10.3. Global Biologics Market, Growth and Market Share Comparison, by Region
11. Biologics Market Segmentation
11.1. Global Biologics Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.1. Global Monoclonal Antibodies (MAbS) Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion) - Anti-Cancer MAbS; Immunological MAbS; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological MABS; Cardiovascular and Cerebrovascular MAbS; Other Monoclonal Antibodies (MAbs)
12.2. Global Therapeutic Proteins Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion) - Metabolic Disorders Therapeutic Proteins; Cancer Therapeutic Proteins; Cardiovascular Therapeutic Proteins; Immunological Therapeutic Proteins; Other Therapeutic Proteins
12.3. Global Vaccines Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion) - Anti-Infective Vaccines; Autoimmunity Vaccines; Other Vaccines
13. Biologics Market Metrics
13.1. Biologics Market Size, Percentage of GDP, 2015-2025, Global
13.2. Per Capita Average Biologics Market Expenditure, 2015-2025, Global
14. Asia-Pacific Biologics Market
14.1. Asia-Pacific Biologics Market Overview
14.3. Asia-Pacific, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
14.4. Asia-Pacific, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
14.5. Asia-Pacific, Biologics Market Metrics
14.5.1. Per Capita Average Biologics Expenditure, 2015-2025, Asia-Pacific Countries
14.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, Asia-Pacific Countries
14.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, Asia-Pacific Countries
14.6. Asia-Pacific Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7. Asia-Pacific Biologics Market: Country Analysis
14.7.1. China Biologics Market
14.7.1.1. China Biologics Market Overview
14.7.1.2. China Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.1.3. China Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.2. Australia Biologics Market
14.7.2.1. Australia Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.2.2. Australia Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.3. Hong Kong Biologics Market
14.7.3.1. Hong Kong Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.4. India Biologics Market
14.7.4.1. India Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.4.2. India Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5. Indonesia Biologics Market
14.7.5.1. Indonesia Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5.2. Indonesia Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6. Japan Biologics Market
14.7.6.1. Japan Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6.2. Japan Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.7. Malaysia Biologics Market
14.7.7.1. Malaysia Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.8. New Zealand Biologics Market
14.7.8.1. New Zealand Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.9. Philippines Biologics Market
14.7.9.1. Philippines Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.10. Singapore Biologics Market
14.7.10.1. Singapore Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.11. South Korea Biologics Market
14.7.11.1. South Korea Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.11.2. South Korea Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.12. Thailand Biologics Market
14.7.12.1. Thailand Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.13. Vietnam Biologics Market
14.7.13.1. Vietnam Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15. Western Europe Biologics Market
15.1. Western Europe Biologics Market Overview
15.2. Western Europe, Biologics Market, 2020, by Country, Value ($ Billion)
15.3. Western Europe, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
15.4. Western Europe, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
15.5. Western Europe, Biologics Market Metrics
15.5.1. Per Capita Average Biologics Expenditure, 2015-2025, Western Europe Countries
15.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, Western Europe Countries
15.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, Western Europe Countries
15.6. Western Europe Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7. Western Europe Biologics Market: Country Analysis
15.7.1. Austria Biologics Market
15.7.1.1. Austria Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.2. Belgium Biologics Market
15.7.2.1. Belgium Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.3. Denmark Biologics Market
15.7.3.1. Denmark Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4. Finland Biologics Market
15.7.4.1. Finland Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.5. France Biologics Market
15.7.5.1. France Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.5.2. France Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.6. Germany Biologics Market
15.7.6.1. Germany Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.6.2. Germany Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.7. Ireland Biologics Market
15.7.7.1. Ireland Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.8. Italy Biologics Market
15.7.8.1. Italy Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.9. Netherlands Biologics Market
15.7.9.1. Netherlands Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.10. Norway Biologics Market
15.7.10.1. Norway Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.11. Portugal Biologics Market
15.7.11.1. Portugal Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.12. Spain Biologics Market
15.7.12.1. Spain Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.13. Sweden Biologics Market
15.7.13.1. Sweden Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.15. Switzerland Biologics Market
15.7.15.1. Switzerland Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.15. UK Biologics Market
15.7.15.1. UK Biologics Market2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.15.2. UK Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16. Eastern Europe Biologics Market
16.1. Eastern Europe Biologics Market Overview
16.2. Eastern Europe, Biologics Market, 2020, by Country, Value ($ Billion)
16.3. Eastern Europe, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
16.4. Eastern Europe, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
16.5. Eastern Europe, Biologics Market Metrics
16.5.1. Per Capita Average Biologics Expenditure, 2015-2025, Eastern Europe Countries
16.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, Eastern Europe Countries
16.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, Eastern Europe Countries
16.6. Eastern Europe Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7. Eastern Europe Biologics Market: Country Analysis
16.7.1. Czech Republic Biologics Market,
16.7.1.1. Czech Republic Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.2. Poland Biologics Market
16.7.2.1. Poland Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3. Romania Biologics Market
16.7.3.1. Romania Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.4. Russia Biologics Market
16.7.4.1. Russia Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.4.2. Russia Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17. North America Biologics Market
17.1. North America Biologics Market Overview
17.2. North America, Biologics Market, 2020, by Country, Value ($ Billion)
17.3. North America, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
17.4. North America, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
17.5. North America, Biologics Market Metrics
17.5.1. Per Capita Average Biologics Expenditure, 2015-2025, North America Countries
17.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, North America Countries
17.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, North America Countries
17.6. North America Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7. North America Biologics Market: Country Analysis
17.7.1. Canada Biologics Market
17.7.1.1. Canada Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2. Mexico Biologics Market
17.7.2.1. Mexico Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.3. USA Biologics Market
17.7.3.1. USA Biologics Market Overview
17.7.3.2. USA Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.3.3. USA Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18. South America Biologics Market
18.1. South America Biologics Market Overview
18.2. South America, Biologics Market, 2020, by Country, Value ($ Billion)
18.3. South America, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
18.4. South America, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
18.5. South America, Biologics Market Metrics
18.5.1. Per Capita Average Biologics Expenditure, 2015-2025, South America Countries
18.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, South America Countries
18.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, South America Countries
18.6. South America Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7. South America Biologics Market: Country Analysis
18.7.1. Argentina Biologics Market
18.7.1.1. Argentina Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.2. Brazil Biologics Market
18.7.1.1. Brazil Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.2.2. Brazil Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.3. Chile Biologics Market
18.7.3.1. Chile Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.4. Colombia Biologics Market
18.7.4.1. Colombia Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.5. Peru Biologics Market
18.7.5.1. Peru Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.6. Venezuela Biologics Market
18.7.6.1. Venezuela Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19. Middle East Biologics Market
19.1. Middle East Biologics Market Overview
19.2. Middle East, Biologics Market, 2020, by Country, Value ($ Billion)
19.3. Middle East, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
19.4. Middle East, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
19.5. Middle East, Biologics Market Metrics
19.5.1. Per Capita Average Biologics Expenditure, 2015-2025, Middle East Countries
19.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, Middle East Countries
19.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, Middle East Countries
19.6. Middle East Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7. Middle East Biologics Market: Country Analysis
19.7.1. Saudi Arabia Biologics Market
19.7.1.1. Saudi Arabia Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.2. Israel Biologics Market
19.7.2.1. Israel Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.3. Turkey Biologics Market
19.7.3.1. Turkey Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.4. UAE Biologics Market
19.7.4.1. UAE Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
20. Africa Biologics Market
20.1. Africa Biologics Market Overview
20.2. Africa, Biologics Market, 2020, by Country, Value ($ Billion)
20.3. Africa, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
20.4. Africa, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
20.5. Africa, Biologics Market Metrics
20.5.1. Per Capita Average Biologics Expenditure, 2015-2025, Africa Countries
20.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, Africa Countries
20.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, Africa Countries
20.6. Africa Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
20.7. Africa Biologics Market: Country Analysis
20.7.1. Egypt Biologics Market
20.7.1.1. Egypt Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
20.7.2. Nigeria Biologics Market
20.7.2.1. Nigeria Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
20.7.3. South Africa Biologics Market
20.7.3.1. South Africa Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
21. Biologics Market Competitive Landscape
21.1. Competitive Market Overview
21.2. Market Shares
21.3. Company Profiles
21.3.1. Johnson & Johnson
21.3.1.1. Company Overview
21.3.1.2. Products and Services
21.3.1.3. Strategy
21.3.1.4. Financial Performance
21.3.2. F. Hoffmann-La Roche Ltd.
21.3.2.1. Company Overview
21.3.2.2. Products and Services
21.3.2.3. Strategy
21.3.2.4. Financial Performance
21.3.3. Bristol-Myers Squibb
21.3.3.1. Company Overview
21.3.3.2. Products and Services
21.3.3.3. Strategy
21.3.3.4. Financial Performance
21.3.4. GlaxoSmithKline Plc.
21.3.4.1. Company Overview
21.3.4.2. Products and Services
21.3.4.3. Strategy
21.3.4.4. Financial Performance
21.3.5. AbbVie
21.3.5.1. Company Overview
21.3.5.2. Products and Services
21.3.5.3. Strategy
21.3.5.4. Financial Performance
22. Key Mergers and Acquisitions in the Biologics Market
23. Market Background: Pharmaceuticals Market
23.1. Pharmaceuticals Market Characteristics
23.2. Pharmaceuticals Market Historic and Forecast, 2015-2020, 2020-2025F, 2030F Growth, by Segment, Value ($ Billion), Global
23.3. Global Pharmaceuticals Market, 2020, by Region, Value ($ Billion)
23.4. Global Pharmaceuticals Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
23.5. Global Pharmaceuticals Market, 2015-2020, 2020-2025F, 2030F, Segmentation by Type, Value ($ Billion)
24. Recommendations
24.1. Global Biologics Market in 2025 - Growth Countries
24.2. Global Biologics Market in 2025 - Growth Segments
24.3. Global Biologics Market in 2025 - Growth Strategies
25. Appendix
25.1. NAICS Definitions of Industry Covered in This Report
25.2. Abbreviations
25.3. Currencies
25.4. Research Inquiries
25.5. About the Publisher
26. Copyright and Disclaimer
2. Report Structure
3. Biologics Market Characteristics
3.1. Market Definition
3.2. Key Segmentations
4. Biologics Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products
5. Biologics Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers
6. Biologics Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth
7. Biologics Market Trends and Strategies
8. Impact of COVID-19 on Biologics
9. Biologics Market Size and Growth
9.1. Market Size
9.2. Historic Market Growth, Value ($ Billion)
9.2.1. Drivers of the Market
9.2.2. Restraints on the Market
9.3. Forecast Market Growth, Value ($ Billion)
9.3.1. Drivers of the Market
9.3.2. Restraints on the Market
10. Biologics Market Regional Analysis
10.1. Global Biologics Market, 2020, by Region, Value ($ Billion)
10.2. Global Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
10.3. Global Biologics Market, Growth and Market Share Comparison, by Region
11. Biologics Market Segmentation
11.1. Global Biologics Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Monoclonal Antibodies (MAbS)
- Therapeutic Proteins
- Vaccines
- Hospital Pharmacies
- Retail Pharmacies/ Drug Stores
- Others
- Oral
- Parenteral
- Others
- Branded Drugs
- Generic Drugs
- Prescription-Based Drugs
- Over-The-Counter Drugs
12.1. Global Monoclonal Antibodies (MAbS) Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion) - Anti-Cancer MAbS; Immunological MAbS; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological MABS; Cardiovascular and Cerebrovascular MAbS; Other Monoclonal Antibodies (MAbs)
12.2. Global Therapeutic Proteins Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion) - Metabolic Disorders Therapeutic Proteins; Cancer Therapeutic Proteins; Cardiovascular Therapeutic Proteins; Immunological Therapeutic Proteins; Other Therapeutic Proteins
12.3. Global Vaccines Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion) - Anti-Infective Vaccines; Autoimmunity Vaccines; Other Vaccines
13. Biologics Market Metrics
13.1. Biologics Market Size, Percentage of GDP, 2015-2025, Global
13.2. Per Capita Average Biologics Market Expenditure, 2015-2025, Global
14. Asia-Pacific Biologics Market
14.1. Asia-Pacific Biologics Market Overview
- Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.3. Asia-Pacific, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
14.4. Asia-Pacific, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
14.5. Asia-Pacific, Biologics Market Metrics
14.5.1. Per Capita Average Biologics Expenditure, 2015-2025, Asia-Pacific Countries
14.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, Asia-Pacific Countries
14.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, Asia-Pacific Countries
14.6. Asia-Pacific Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7. Asia-Pacific Biologics Market: Country Analysis
14.7.1. China Biologics Market
14.7.1.1. China Biologics Market Overview
14.7.1.2. China Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.1.3. China Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.2. Australia Biologics Market
14.7.2.1. Australia Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.2.2. Australia Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.3. Hong Kong Biologics Market
14.7.3.1. Hong Kong Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.4. India Biologics Market
14.7.4.1. India Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.4.2. India Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5. Indonesia Biologics Market
14.7.5.1. Indonesia Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.5.2. Indonesia Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6. Japan Biologics Market
14.7.6.1. Japan Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.6.2. Japan Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.7. Malaysia Biologics Market
14.7.7.1. Malaysia Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.8. New Zealand Biologics Market
14.7.8.1. New Zealand Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.9. Philippines Biologics Market
14.7.9.1. Philippines Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.10. Singapore Biologics Market
14.7.10.1. Singapore Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.11. South Korea Biologics Market
14.7.11.1. South Korea Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.11.2. South Korea Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.12. Thailand Biologics Market
14.7.12.1. Thailand Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
14.7.13. Vietnam Biologics Market
14.7.13.1. Vietnam Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15. Western Europe Biologics Market
15.1. Western Europe Biologics Market Overview
15.2. Western Europe, Biologics Market, 2020, by Country, Value ($ Billion)
15.3. Western Europe, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
15.4. Western Europe, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
15.5. Western Europe, Biologics Market Metrics
15.5.1. Per Capita Average Biologics Expenditure, 2015-2025, Western Europe Countries
15.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, Western Europe Countries
15.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, Western Europe Countries
15.6. Western Europe Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7. Western Europe Biologics Market: Country Analysis
15.7.1. Austria Biologics Market
15.7.1.1. Austria Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.2. Belgium Biologics Market
15.7.2.1. Belgium Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.3. Denmark Biologics Market
15.7.3.1. Denmark Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.4. Finland Biologics Market
15.7.4.1. Finland Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.5. France Biologics Market
15.7.5.1. France Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.5.2. France Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.6. Germany Biologics Market
15.7.6.1. Germany Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.6.2. Germany Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.7. Ireland Biologics Market
15.7.7.1. Ireland Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.8. Italy Biologics Market
15.7.8.1. Italy Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.9. Netherlands Biologics Market
15.7.9.1. Netherlands Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.10. Norway Biologics Market
15.7.10.1. Norway Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.11. Portugal Biologics Market
15.7.11.1. Portugal Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.12. Spain Biologics Market
15.7.12.1. Spain Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.13. Sweden Biologics Market
15.7.13.1. Sweden Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.15. Switzerland Biologics Market
15.7.15.1. Switzerland Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.15. UK Biologics Market
15.7.15.1. UK Biologics Market2015-2020, 2020-2025F, 2030F, Value ($ Billion)
15.7.15.2. UK Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16. Eastern Europe Biologics Market
16.1. Eastern Europe Biologics Market Overview
16.2. Eastern Europe, Biologics Market, 2020, by Country, Value ($ Billion)
16.3. Eastern Europe, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
16.4. Eastern Europe, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
16.5. Eastern Europe, Biologics Market Metrics
16.5.1. Per Capita Average Biologics Expenditure, 2015-2025, Eastern Europe Countries
16.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, Eastern Europe Countries
16.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, Eastern Europe Countries
16.6. Eastern Europe Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7. Eastern Europe Biologics Market: Country Analysis
16.7.1. Czech Republic Biologics Market,
16.7.1.1. Czech Republic Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.2. Poland Biologics Market
16.7.2.1. Poland Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.3. Romania Biologics Market
16.7.3.1. Romania Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.4. Russia Biologics Market
16.7.4.1. Russia Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
16.7.4.2. Russia Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17. North America Biologics Market
17.1. North America Biologics Market Overview
17.2. North America, Biologics Market, 2020, by Country, Value ($ Billion)
17.3. North America, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
17.4. North America, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
17.5. North America, Biologics Market Metrics
17.5.1. Per Capita Average Biologics Expenditure, 2015-2025, North America Countries
17.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, North America Countries
17.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, North America Countries
17.6. North America Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7. North America Biologics Market: Country Analysis
17.7.1. Canada Biologics Market
17.7.1.1. Canada Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.2. Mexico Biologics Market
17.7.2.1. Mexico Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.3. USA Biologics Market
17.7.3.1. USA Biologics Market Overview
17.7.3.2. USA Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
17.7.3.3. USA Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18. South America Biologics Market
18.1. South America Biologics Market Overview
18.2. South America, Biologics Market, 2020, by Country, Value ($ Billion)
18.3. South America, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
18.4. South America, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
18.5. South America, Biologics Market Metrics
18.5.1. Per Capita Average Biologics Expenditure, 2015-2025, South America Countries
18.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, South America Countries
18.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, South America Countries
18.6. South America Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7. South America Biologics Market: Country Analysis
18.7.1. Argentina Biologics Market
18.7.1.1. Argentina Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.2. Brazil Biologics Market
18.7.1.1. Brazil Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.2.2. Brazil Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.3. Chile Biologics Market
18.7.3.1. Chile Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.4. Colombia Biologics Market
18.7.4.1. Colombia Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.5. Peru Biologics Market
18.7.5.1. Peru Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
18.7.6. Venezuela Biologics Market
18.7.6.1. Venezuela Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19. Middle East Biologics Market
19.1. Middle East Biologics Market Overview
19.2. Middle East, Biologics Market, 2020, by Country, Value ($ Billion)
19.3. Middle East, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
19.4. Middle East, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
19.5. Middle East, Biologics Market Metrics
19.5.1. Per Capita Average Biologics Expenditure, 2015-2025, Middle East Countries
19.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, Middle East Countries
19.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, Middle East Countries
19.6. Middle East Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7. Middle East Biologics Market: Country Analysis
19.7.1. Saudi Arabia Biologics Market
19.7.1.1. Saudi Arabia Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.2. Israel Biologics Market
19.7.2.1. Israel Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.3. Turkey Biologics Market
19.7.3.1. Turkey Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
19.7.4. UAE Biologics Market
19.7.4.1. UAE Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
20. Africa Biologics Market
20.1. Africa Biologics Market Overview
20.2. Africa, Biologics Market, 2020, by Country, Value ($ Billion)
20.3. Africa, Biologics Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Country
20.4. Africa, Biologics Market, 2015-2020, 2020-2025F, 2030F, Growth and Market Share Comparison, by Country
20.5. Africa, Biologics Market Metrics
20.5.1. Per Capita Average Biologics Expenditure, 2015-2025, Africa Countries
20.5.2. Number of Enterprises, Biologics Market, Biologics Market/Number of Enterprises, 2020, Africa Countries
20.5.3. Number of Employees, Biologics Market, Biologics Market/Number of Employees, 2020, Africa Countries
20.6. Africa Biologics Market, Segmentation by Type, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
20.7. Africa Biologics Market: Country Analysis
20.7.1. Egypt Biologics Market
20.7.1.1. Egypt Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
20.7.2. Nigeria Biologics Market
20.7.2.1. Nigeria Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
20.7.3. South Africa Biologics Market
20.7.3.1. South Africa Biologics Market, 2015-2020, 2020-2025F, 2030F, Value ($ Billion)
21. Biologics Market Competitive Landscape
21.1. Competitive Market Overview
21.2. Market Shares
21.3. Company Profiles
21.3.1. Johnson & Johnson
21.3.1.1. Company Overview
21.3.1.2. Products and Services
21.3.1.3. Strategy
21.3.1.4. Financial Performance
21.3.2. F. Hoffmann-La Roche Ltd.
21.3.2.1. Company Overview
21.3.2.2. Products and Services
21.3.2.3. Strategy
21.3.2.4. Financial Performance
21.3.3. Bristol-Myers Squibb
21.3.3.1. Company Overview
21.3.3.2. Products and Services
21.3.3.3. Strategy
21.3.3.4. Financial Performance
21.3.4. GlaxoSmithKline Plc.
21.3.4.1. Company Overview
21.3.4.2. Products and Services
21.3.4.3. Strategy
21.3.4.4. Financial Performance
21.3.5. AbbVie
21.3.5.1. Company Overview
21.3.5.2. Products and Services
21.3.5.3. Strategy
21.3.5.4. Financial Performance
22. Key Mergers and Acquisitions in the Biologics Market
23. Market Background: Pharmaceuticals Market
23.1. Pharmaceuticals Market Characteristics
23.2. Pharmaceuticals Market Historic and Forecast, 2015-2020, 2020-2025F, 2030F Growth, by Segment, Value ($ Billion), Global
23.3. Global Pharmaceuticals Market, 2020, by Region, Value ($ Billion)
23.4. Global Pharmaceuticals Market, 2015-2020, 2020-2025F, 2030F, Historic and Forecast, by Region
23.5. Global Pharmaceuticals Market, 2015-2020, 2020-2025F, 2030F, Segmentation by Type, Value ($ Billion)
24. Recommendations
24.1. Global Biologics Market in 2025 - Growth Countries
24.2. Global Biologics Market in 2025 - Growth Segments
24.3. Global Biologics Market in 2025 - Growth Strategies
25. Appendix
25.1. NAICS Definitions of Industry Covered in This Report
25.2. Abbreviations
25.3. Currencies
25.4. Research Inquiries
25.5. About the Publisher
26. Copyright and Disclaimer
Note: Product cover images may vary from those shown
3 of 5
FEATURED COMPANIES
- AbbVie
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc.
- Johnson & Johnson
- MORE
Major companies in the biologics market include Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb; GlaxoSmithKline Plc. and AbbVie.
The global biologics market is expected to grow from $253.41 billion in 2020 to $268.51 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $420.55 billion in 2025 at a CAGR of 12%.
The biologics market consists of sales of biologics and related services by entities (organizations, sole traders and partnerships) that produce biologics to treat and prevent various microbial diseases and cancers. Biological products include a wide range of products such as vaccines, allergenics, somatic cells, tissues, and recombinant therapeutic proteins. This industry includes establishments that produce products that are composed of sugars, proteins, nucleic acids, and combination of all these substances isolated from humans, animal and microorganisms or produced from biotechnology methods. Specifically, most biologic medicines are developed using recombinant DNA (rDNA) technology. The biologics market is segmented into monoclonal antibodies (mabs); therapeutic proteins; and vaccines.
North America was the largest region in the global biologics market, accounting for 53% of the market in 2020. Asia Pacific was the second largest region accounting for 21% of the global biologics market. Africa was the smallest region in the global biologics market.
The US Food and Drug Administration (FDA) has revised its regulations to eliminate outdated biologics requirements, thus allowing drug manufacturers to employ new manufacturing technologies and testing capabilities. Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure safety, purity and potency of biologics can now be obtained from sources other than FDA’s Center for Biologics Evaluation and Research (CBER), or can be developed internally by the biologics license applicant. The FDA has also removed a rule (Section 610.21 of FDA code) which specifies minimal potency limits to be met for certain antibodies and antigens. In addition, FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. These amendments in regulations are expected to increase regulatory flexibility by allowing the pharmaceutical industry and the FDA to incorporate current scientific technologies in the manufacture of licensed biological products.
The early generation of biologics is losing its patent protection and are expected to face greater competition going forward from the entry of biosimilars into the market. Biosimilars are the pharmaceuticals that are developed to have similar properties to a biologic drug that has already been approved. Demand for biosimilars is being fueled by governments around the world trying to reduce healthcare costs. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilars industry. In the EU, a pathway for approving biosimilar medicines has existed since 2003. These less expensive alternatives increase competitiveness for the biologics market putting downward pressure on pricing and market value growth.
Technology is expected to be a continued driver of market growth during this period. An area of particular development is likely to be physiology simulation modeling. Markets such as this one will benefit from the greater efficiencies offered by developments in this area. For example, Eli Lilly and Pfizer have adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models in early drug discovery that have been operational within hours, whereas traditional models would have taken weeks to conduct simulations. The Open Innovation Drug Discovery program is another initiative by Lilly to enhance the research and development of biologics. Such technological advances are likely to reduce costs and expedite the development phase of biologics, allowing companies to launch their products early.
The global biologics market is expected to grow from $253.41 billion in 2020 to $268.51 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $420.55 billion in 2025 at a CAGR of 12%.
The biologics market consists of sales of biologics and related services by entities (organizations, sole traders and partnerships) that produce biologics to treat and prevent various microbial diseases and cancers. Biological products include a wide range of products such as vaccines, allergenics, somatic cells, tissues, and recombinant therapeutic proteins. This industry includes establishments that produce products that are composed of sugars, proteins, nucleic acids, and combination of all these substances isolated from humans, animal and microorganisms or produced from biotechnology methods. Specifically, most biologic medicines are developed using recombinant DNA (rDNA) technology. The biologics market is segmented into monoclonal antibodies (mabs); therapeutic proteins; and vaccines.
North America was the largest region in the global biologics market, accounting for 53% of the market in 2020. Asia Pacific was the second largest region accounting for 21% of the global biologics market. Africa was the smallest region in the global biologics market.
The US Food and Drug Administration (FDA) has revised its regulations to eliminate outdated biologics requirements, thus allowing drug manufacturers to employ new manufacturing technologies and testing capabilities. Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure safety, purity and potency of biologics can now be obtained from sources other than FDA’s Center for Biologics Evaluation and Research (CBER), or can be developed internally by the biologics license applicant. The FDA has also removed a rule (Section 610.21 of FDA code) which specifies minimal potency limits to be met for certain antibodies and antigens. In addition, FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. These amendments in regulations are expected to increase regulatory flexibility by allowing the pharmaceutical industry and the FDA to incorporate current scientific technologies in the manufacture of licensed biological products.
The early generation of biologics is losing its patent protection and are expected to face greater competition going forward from the entry of biosimilars into the market. Biosimilars are the pharmaceuticals that are developed to have similar properties to a biologic drug that has already been approved. Demand for biosimilars is being fueled by governments around the world trying to reduce healthcare costs. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilars industry. In the EU, a pathway for approving biosimilar medicines has existed since 2003. These less expensive alternatives increase competitiveness for the biologics market putting downward pressure on pricing and market value growth.
Technology is expected to be a continued driver of market growth during this period. An area of particular development is likely to be physiology simulation modeling. Markets such as this one will benefit from the greater efficiencies offered by developments in this area. For example, Eli Lilly and Pfizer have adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models in early drug discovery that have been operational within hours, whereas traditional models would have taken weeks to conduct simulations. The Open Innovation Drug Discovery program is another initiative by Lilly to enhance the research and development of biologics. Such technological advances are likely to reduce costs and expedite the development phase of biologics, allowing companies to launch their products early.
Note: Product cover images may vary from those shown
4 of 5
- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb
- GlaxoSmithKline Plc.
- AbbVie
Note: Product cover images may vary from those shown
5 of 5
LOADING...
